➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
McKinsey
Mallinckrodt
Moodys
Boehringer Ingelheim

Last Updated: June 12, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for TA-8995


Email this page to a colleague

« Back to Dashboard

What is the drug development status for TA-8995?

TA-8995 is an investigational drug.

There have been 8 clinical trials for TA-8995. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Dyslipidemias and [disabled in preview]. The leading clinical trial sponsors are Xention Ltd, Mitsubishi Tanabe Pharma Corporation, and [disabled in preview].

There are three US patents protecting this investigational drug and sixty-seven international patents.

Recent Clinical Trials for TA-8995
TitleSponsorPhase
Bioequivalence Study of Capsule and Tablet Formulations of TA-8995Xention LtdPhase 1
ADME Study in Healthy Male Subjects With TA-8995Xention LtdPhase 1
A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)Xention LtdPhase 1/Phase 2

See all TA-8995 clinical trials

Clinical Trial Summary for TA-8995

Top disease conditions for TA-8995
Top clinical trial sponsors for TA-8995

See all TA-8995 clinical trials

US Patents for TA-8995

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TA-8995   Get Started Free Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives DEZIMA PHARMA B.V. (Naarden, NL)   Get Started Free
TA-8995   Get Started Free Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors DEZIMA PHARMA B.V. (NL)   Get Started Free
TA-8995   Get Started Free Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases DEZIMA PHARMA BV (NL)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TA-8995

Drugname Country Document Number Estimated Expiration Related US Patent
TA-8995 Argentina AR101509 2034-08-12   Get Started Free
TA-8995 Australia AU2015302407 2034-08-12   Get Started Free
TA-8995 Brazil BR112017002873 2034-08-12   Get Started Free
TA-8995 Canada CA2958040 2034-08-12   Get Started Free
TA-8995 Chile CL2017000367 2034-08-12   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
McKinsey
Johnson and Johnson
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.